INTS — Intensity Therapeutics, Inc. Common stock
NASDAQ · Healthcare · Biotechnology
$4.11
+$0.04 (+0.86%)
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on NASDAQ. It is led by Lewis H. Bender M.A., M.B.A., M.S., based in 1 Enterprise Drive, Shelton, CT, United States, 06484-4779, with about 5 employees. Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Net income was -$2.7M. INTS currently screens at market cap $7.7M.
Use this INTS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the INTS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the INTS SEC filings page. Lician reads the product cache first so this HTML stays unique to Intensity Therapeutics, Inc. Common stock even when a live quote feed is slow.
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
INTS Key Statistics
Market Cap
$7.69M
Volume
75,194
Previous Close
$4.53
Day Range
$4.19 – $4.70
EPS
-$1.17
Revenue
$0.00
Net Income
-$16.27M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
5
INTS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$16.27M | -$10.54M | -$7.58M |
| EPS (Diluted) | -$1.17 | -$1.38 | -$2.22 |
Total Assets
$4.78M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$428.00K
Operating Cash Flow
-$15.22M
Free Cash Flow
$0.00
Intensity Therapeutics, Inc. Common stock Company Information
- Founder, President, CEO & Chairman of the Board
- Lewis H. Bender M.A., M.B.A., M.S.
- Headquarters
- 1 Enterprise Drive, Shelton, CT, United States, 06484-4779
- Phone
- 203 221 7381
- IPO / Founded
- 2023-06-30
- Sector
- Healthcare
- Industry
- Biotechnology